BioMark
生物标记
基本信息
- 批准号:8446911
- 负责人:
- 金额:$ 32.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-07-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:Advisory CommitteesAntigensB-LymphocytesBooksCellsCollectionCommitCommunitiesContractsCore FacilityDNAEquipmentFluorescence-Activated Cell SortingGenomicsGenotypeHeadHeterogeneityHousingHuman ResourcesImmune responseImmunologyInstitutesInstitutionLabelMaintenanceMalignant NeoplasmsManufacturer NameMicrofluidicsMusNeuronsOutputPopulationRecoveryResearch InstituteResearch PersonnelResourcesScienceScientistSiteSupervisionT-LymphocyteTimeTrainingabstractingcostdigitalinstrumentmanmicrobialnew technologyoperationprogramsresearch studysingle cell analysisstemtumor
项目摘要
DESCRIPTION (provided by applicant):
Project Summary and Abstract This proposal by the Scripps Research Institute is aimed at purchasing a Biomark instrument from Fluidigm. This instrument will be dedicated to studying single cells at the transcriptional and respond to an increasing demand from the scientists of TSRI. The Institute is committed to fully support this application that stems from the Department of Immunology and Microbial Science. The necessary resources and personnel needed for operation will committed through housing the new instrument within the DNA Core of TSRI under the supervision of the Core director, Steven Head. Our request for a Biomark machine is motivated by the urgent need to bring to our institution a new technology that will allow experiments that cannot currently be carried out on-site and that will add to the quality of our output. This microfluidic machine has the huge advantage of versatility as it can be used for real-time PCR, digital PCR, genotyping, and sequencing. With respect to single cell analysis, we could not find comparable pieces of equipment from any of the competitive genomics hardware companies. In immunology, the need to study single cells has exploded over the past few years as the community has now realized of the heterogeneity of cell populations. This new way of looking at the immune response has been greatly facilitated by our capacity to isolate specific single B and T cells by fluorescence activated cell sorting using labeled antigens and labeled MHC multimers, respectively. The current hurdle is the limited ability that we have to extract multiparametric information from the isolated single cell. Similarly, neurobiologists want to interrogate single neurons and cancer biologist want to examine tumor heterogeneity. The instrument will be housed in and operated by the TSRI DNA Core Facility. For immunological applications the entire collection of primers will be available at cost to investigators. Indeed, te collection of primer sets needed for immunological applications is very standardized in both mouse and man and can be easily categorized. As a core instrument, the Biomark will be available to all investigators on campus under the supervision of the core director and its advisory committee. The core will be capable of providing basic training although formal manufacturer training will be highly encouraged before using the instrument. Booking will be on-line and under the supervision of the core director. The instrument will be under a maintenance contract paid by a cost-recovery program.
描述(由申请人提供):
项目概要和摘要 斯克里普斯研究所的这项提案旨在从 Fluidigm 购买 Biomark 仪器。该仪器将致力于研究单细胞的转录,并响应 TSRI 科学家日益增长的需求。该研究所致力于全力支持这项源自免疫学和微生物科学系的应用。运营所需的必要资源和人员将通过将新仪器安置在 TSRI 的 DNA 核心内并在核心主任 Steven Head 的监督下进行承诺。我们对 Biomark 机器的需求是因为迫切需要为我们的机构带来一项新技术,该技术将允许目前无法在现场进行的实验,并提高我们的产出质量。该微流控机器具有多功能性的巨大优势,可用于实时PCR、数字PCR、基因分型和测序。在单细胞分析方面,我们无法从任何具有竞争力的基因组学硬件公司找到类似的设备。在免疫学中,随着社会现在意识到细胞群的异质性,研究单细胞的需求在过去几年中呈爆炸式增长。我们分别使用标记的抗原和标记的 MHC 多聚体通过荧光激活细胞分选来分离特定的单个 B 和 T 细胞的能力极大地促进了这种观察免疫反应的新方法。当前的障碍是我们从孤立的单细胞中提取多参数信息的能力有限。同样,神经生物学家想要询问单个神经元,癌症生物学家想要检查肿瘤异质性。该仪器将安装在 TSRI DNA 核心设施内并由 TSRI DNA 核心设施运行。对于免疫学应用,研究人员可以付费获得整个引物集。事实上,免疫学应用所需的引物组集合在小鼠和人类中都非常标准化,并且可以轻松分类。作为核心工具,Biomark 将在核心主任及其咨询委员会的监督下向校园内的所有研究人员开放。尽管强烈鼓励在使用仪器之前进行正式的制造商培训,但核心将能够提供基本培训。预订将在网上进行,并在核心总监的监督下进行。该仪器将签订维护合同,由成本回收计划支付费用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Luc Teyton其他文献
Luc Teyton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Luc Teyton', 18)}}的其他基金
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
- 批准号:
10549640 - 财政年份:2023
- 资助金额:
$ 32.17万 - 项目类别:
Leveraging Human iPSC-derived beta-cells to Probe Antigen Specificity of Anti-islet Memory T Cells in T1D
利用人 iPSC 衍生的 β 细胞探测 T1D 中抗胰岛记忆 T 细胞的抗原特异性
- 批准号:
10589556 - 财政年份:2023
- 资助金额:
$ 32.17万 - 项目类别:
Molecular basis of glycan recognition by T and B cells
T 和 B 细胞识别聚糖的分子基础
- 批准号:
10549648 - 财政年份:2023
- 资助金额:
$ 32.17万 - 项目类别:
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines
疫苗中针对 B 细胞的组合佐剂的机理研究
- 批准号:
10218993 - 财政年份:2021
- 资助金额:
$ 32.17万 - 项目类别:
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines
疫苗中针对 B 细胞的组合佐剂的机理研究
- 批准号:
10397167 - 财政年份:2021
- 资助金额:
$ 32.17万 - 项目类别:
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines
疫苗中针对 B 细胞的组合佐剂的机理研究
- 批准号:
10599324 - 财政年份:2021
- 资助金额:
$ 32.17万 - 项目类别:
Early diagnosis and mechanistic studies of type 1 diabetes using single cell analysis
使用单细胞分析进行 1 型糖尿病的早期诊断和机制研究
- 批准号:
9884757 - 财政年份:2019
- 资助金额:
$ 32.17万 - 项目类别:
Early diagnosis and mechanistic studies of type 1 diabetes using single cell analysis
使用单细胞分析进行 1 型糖尿病的早期诊断和机制研究
- 批准号:
10362605 - 财政年份:2019
- 资助金额:
$ 32.17万 - 项目类别:
相似国自然基金
B淋巴细胞表面抗原CD20介导趋化因子CCL7释放招募单核细胞促进心力衰竭的机制
- 批准号:82170385
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
高同型半胱氨酸血症上调B淋巴细胞抗原提呈而促进动脉粥样硬化发病
- 批准号:
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
草鱼IgM+髓样细胞与IgM+B淋巴细胞具有吞噬和抗原递呈功能的细胞和分子机制
- 批准号:31972824
- 批准年份:2019
- 资助金额:58 万元
- 项目类别:面上项目
人工APCs刺激T细胞对CD19-CD20-CAR在B淋巴细胞瘤治疗效果的研究
- 批准号:81802848
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
双靶向CD19/CD22嵌合抗原受体治疗急性B淋巴细胞白血病的应用基础研究
- 批准号:81602711
- 批准年份:2016
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Improving phage-based medicine with immunoengineering
通过免疫工程改进基于噬菌体的医学
- 批准号:
10572011 - 财政年份:2023
- 资助金额:
$ 32.17万 - 项目类别:
Project 4: Off-the-shelf engineered cord blood-derived natural killer cells for the treatment acute lymphoblastic leukemia
项目 4:现成的工程化脐带血自然杀伤细胞,用于治疗急性淋巴细胞白血病
- 批准号:
10931069 - 财政年份:2023
- 资助金额:
$ 32.17万 - 项目类别:
Harnessing single cell RNA sequencing and integrative bioinformatics to identify precision therapeutics for dermatomyositis
利用单细胞 RNA 测序和综合生物信息学确定皮肌炎的精准治疗方法
- 批准号:
10573015 - 财政年份:2023
- 资助金额:
$ 32.17万 - 项目类别:
Delineating the mechanisms by which tumor immunity multicellular networks shape T cell state
描述肿瘤免疫多细胞网络塑造 T 细胞状态的机制
- 批准号:
10662688 - 财政年份:2023
- 资助金额:
$ 32.17万 - 项目类别:
Characterizing molecular phenotypes of pancreatic islet reactive B cells in T1D through single cell sequencing
通过单细胞测序表征 T1D 中胰岛反应性 B 细胞的分子表型
- 批准号:
10600510 - 财政年份:2023
- 资助金额:
$ 32.17万 - 项目类别: